NON-MALIGNANT DISEASES OF THE ENDOCRINE SYSTEM THROUGH 30 YEARS AFTER CHERNOBYL ACCIDENT
Keywords:Chernobyl accident, suffered due to an accident, ionizing radiation, children, endocrine system.
A retrospective analysis of data 1992–2014 years shows that the prevalence of thyroid patology in people affected by the Chernobyl accident is 40.3 %, in emergency workers — 35.4 %, in those whowere evacuated from the exclusion zone — 27.2 %, in residents of radiation contaminated areas — 28.6 %. It’s significantly higher (p < 0.0001) than in the general Ukrainian population (3.9 %). The most common non-malignant endocrine diseases in individuals who have suffered as a result of the Chernobyl accident were: nodular goiter — 14.4 %, chronic autoimmune thyroiditis 8 %, preobese/obesity 41.9 %/36.8 %, pre-diabetes/diabetes 15.5 %/21.4 %. The most common non-malignant endocrine diseases liquidators of the Chernobyl accident were nodular goiter — 21.8 %, chronic autoimmune thyroiditis — 12.9 %, pre-obese/obesity — 41.7 %/33.6 %, prediabetes/diabetes — 8.6 %/12.2 %. Critical groups were children evacuated from the 30 km exclusion zone and irradiated at the age of 3–6 years. They had diffuse toxic goiter in 43.7 %, chronic autoimmune thyroiditis — 1.7 %, primary hypothyroidism — 0.96 %, nodular goiter — 2.3 %, and the peak prevalence of chronic autoimmune thyroiditis occurred in 2001–2003. An active period of their puberty. Among children who were born from irradiated parents (first generation), thyroid disease was detected in 42.6 %, it exceeded the rate in the control group, chronic autoimmune thyroiditis diagnosed significantly less frequently — at 0.45 %, diffuse toxic goiter in 9.5–13.8 %, nodular goiter at 1.7 %. Non-malignant endocrine pathology in exposed adults and children is common, occurs in 3–53 % of individuals, occurs in the majority of victims in 10–15 years after exposure to the radiation factor in the result of technogenic accident or incident, it continues to grow slowly in 30 years.
Kaminskyi OV, Afanasyev DY, Kopilova O, et al. 75th Scientific Sessions American Diabetes Association’s June 5–9, 2015, Boston.
Kamins’kyj OV. Problemy radiacijnoi’ medycyny ta radiobiologii’: Zb nauk pr, 2014; 19:256-266.
Kamins’kyj OV, Pronin OV, Afanas’jev DJe. Problemy radiacijnoi’ medycyny ta radiobiologii’: Zb nauk pr, 2014; 19:267-276.
Shimizu Y, Kodama K, Nishi N, et al. BMJ 2010; 340:b5349, available at: http://www.bmj.com /content/340/bmj.b5349.
Kazakov VS, Demidchik EP, Astakhova LN. Nature 1992; 359:21.
Shore RE, Hildreth N, Dvoretsky P, et al. Am J Epidemiol 1993; 137;1068-1080.
Schneider AB, Ron E, Lubin J, et al. J Clin Endocrinol Metab 1993; 77:362-369.
Ron E, Lubin JH, Shore RE, et al. Radiat Res 1995; 141:259-277.
Yoshimoto Y, Ezaki H, Etoh R, et al. Radiat Res 1995; 141:278-286.
Völzke H, Werner A, Wallaschofski H, et al. Endocrine Care 2005; 90(8):4587.
Nagataki S, Shibata Y, Inoue S, et al. JAMA 1994; 272:364-370.
Hamilton TE, van Belle G, LoGerfo JP. JAMA 1987; 258:629-636.
Kerber R, Till JE, Simon SL, et al. JAMA 1993; 270:2076-2082.
Imaizumi M, Usa T, Tominaga T, et al. JAMA 2006; 295(9):1011-1022.
Davis S, Kopecky KJ, Hamilton TE, Onstad L. JAMA 2004; 292(21):2600-2613.
Pacini F, Vorontsova T, Molinaro E, et al. Lancet 1998; 352:763-766.
Boehm BO, Steinert M, Dietrich JW, et al. Endocrinology 2009; 160(4):625-630.
Imaizumi M, Sera N, Ueki I, et al. Thyroid 2011; 21(11):1177-1182.
Agate L, Mariotti S, Elisei R, et al. J Clin Endocrinol Metab 2008; 93(7):2729-2736.
Vermiglio F, Castagna MG, Volnova E, et al. Thyroid 1999; 9:781-786.
Ito M, Yamashita S, Ashizawa K, et al. Thyroid 1995; 5:365-368.
Buzunov VA, Pirogova EA, Krasnikova LI, et al. Zhurn NAMN Ukrai’ny 2006; 12(1):174-184.
Larin OS, Pan’kiv VI, Selivanenko MI, Grachova OO. Mizhnar Endokrynol Zhurn 2011; 3(35):10-18.
Vathaire F, El-Fayech C, Fedhila F, et al. Lancet Oncol 2012; 13(10):1002-1010.